Keyword: Flemming Ornskov
Roche’s Genentech is out with a new threat to Shire’s hemophilia franchise—but the Dublin drugmaker’s CEO isn’t too concerned.
Shire CEO Flemming Ornskov acknowledged he could have done more to help investors understand the transition the company is making.
In one CEO popularity contest, biopharma chiefs are pretty average. But some top execs, including CEOs at Roche, AbbVie and Merck & Co., won kudos.
Rare disease drugmakers get that their typically high prices are under the lens these days—just like everyone else’s. But they don’t all necessarily agree that the scrutiny is fair.
The J.P. Morgan Healthcare Conference is starting to wind down in San Francisco, but that doesn't mean the news has diminished.
Deal talk is pretty hard to ignore at the J.P. Morgan Healthcare Conference—especially for a pair of the world’s biggest hemophilia drugmakers.
Expecting $500 million in cost savings from swallowing Baxalta? Scratch that. New owner Shire now says it can up that figure by 40%.
Shire’s long-delayed ADHD candidate has racked up more positive data in its quest to finally make it to market. But will it find space to compete?